Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

ClinicalTrials.gov ID: NCT04629703

Public ClinicalTrials.gov record NCT04629703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT04629703
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Rigel Pharmaceuticals
Industry
Enrollment
280 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 100 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 24, 2021
Primary completion
Sep 4, 2022
Completion
Sep 4, 2022
Last update posted
Aug 17, 2023

2021 – 2022

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
9
Facility City State ZIP Site status
University of California Irvine Orange California 92868
George Washington University Hospital Washington D.C. District of Columbia 20037
Alternative Research Associates, LLC Hialeah Florida 33012
Alternative Research Associates, LLC Miami Florida 33143
Loyola University Medical School Maywood Illinois 60600
Harvard Medical School- Bringham and Women's Hospital Boston Massachusetts 02115
Henry Ford Detroit Michigan 48202
Ascension Medical Group- St. John Clinic Infectious Disease Tulsa Oklahoma 74101
Houston Methodist Research Institute Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04629703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 17, 2023 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04629703 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →